Lisraya is the first oral dual TYK2/JAK1 inhibitor indicated for adults with dermatomyositis, demonstrating significant ...
FDA approves updated 2026-2027 COVID-19 vaccine formulations targeting the XFG variant for older adults and high-risk ...
The FDA expanded tirzepatide's indication to include major adverse cardiovascular event reduction in adults with type 2 diabetes and established CV risk.
A daily single-tablet combination of bictegravir and lenacapavir offers a simplified treatment option for virologically suppressed adults with HIV-1.
The risk for antenatal complications is increased in association with maternal multiple long-term conditions (MLTCs), according to a study published in the Sept ...
HealthDay News — Baseline cortical atrophy measured within the early-onset Alzheimer disease (EOAD) signature, a set of predominantly parietotemporal regions showing greater atrophy in EOAD than in ...
HealthDay News — Paternal exposure to valproate during sperm development is not associated with neurodevelopmental disorders (NDDs) in offspring, according to a study published online August 19 in ...
The FDA has approved Tivicay PD dispersible tablets for combination HIV-1 treatment in full-term neonates weighing at least 2kg.
Interim Phase 1b/2a trial data support the MKK4 inhibitor's potential to protect hepatocytes and accelerate liver regeneration following surgical resection.
The novel nitric oxide-donating prostaglandin analog met noninferiority endpoints vs latanoprost across two phase 3 trials.
Phase 3 RASolute 302 data show daraxonrasib significantly extended overall and progression free survival compared with ...
Imaavy (nipocalimab-aahu) is the first FcRn blocker approved to treat warm autoimmune hemolytic anemia in patients aged 12 years and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results